Glucagon‐Like Peptide‐1 Receptor Agonist Utilization Among Sleep Surgery Clinic Patients

OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are approved to treat obstructive sleep apnea (OSA), yet their use in an OSA population has not been characterized. This study evaluates GLP-1 RA use in patients presenting to a sleep surgery clinic. STUDY DESIGN: Retrospective. SETTING: Tertiary care institution. METHODS: Patients with OSA who presented to our sleep surgery clinic between October 2023 and March 2025 with available sleep studies were included (n = 384). Demographic data, body mass index (BMI), apnea-hypopnea index (AHI), OSA history, GLP-1 RA prescription data, and usage details were collected through chart review. Eligibility for GLP-1 RA was defined by FDA drug labeling criteria, with diabetes, obesity, or BMI ≥ 27 kg/m² with a weight-related comorbidity. RESULTS: (adjusted odds ratio 3.45, P < .001) was associated with higher likelihood. CONCLUSION: Among sleep surgery clinic patients, a large proportion were eligible for GLP-1 RA use, and utilization was high compared to that of the general population.